Sergio Ramírez-González, E. Casillas-Casillas, F. Jaramillo-Juárez, A. Rincón-Sánchez
{"title":"银杏叶提取物761降低老年性黄斑变性进展的风险","authors":"Sergio Ramírez-González, E. Casillas-Casillas, F. Jaramillo-Juárez, A. Rincón-Sánchez","doi":"10.19052/sv.vol20.iss2.7","DOIUrl":null,"url":null,"abstract":"Age-related macular degeneration (AMD) is the leading cause of blindness. Although its\ndevelopment is poorly understood., high concentrations of reactive oxygen species, maybe trigger\nit. The aim of this study was to analyze whether the antioxidant action of the dietary supplement\nGinkgo biloba (EGb-761) can reduce the progression of AMD. A clinical trial was conducted in\nMexico, with people over 55 years of age. AMD patients were treated with EGb-761: 50 mg/day\n(n = 26) or 100 mg/day (n = 22) for 3 months. A control group with 22 healthy people (without\ntreatment) was included. Before and after treatment, functional and structural ocular tests were\nperformed, and systemic oxidative stress (OS) was measured.Changes between baseline and after\nthe treatment with both doses were significant (P < 0.05). Contrast sensitivity increased 16% and\n17%, the number of metamorphopsias (central vision integrity) decreased 100% and 95%;\ncentral perimetry (scotoma) decreased 93% and 88%, and hyperpigmentation\n(autofluorescence) decreased 88% and 89%, respectively. For OS, malondialdehyde\nconcentration decreased 7.6% and 8.5%, and reduced glutathione levels increased 5.3% and\n7.1%, respectively. We suggest giving low doses of Gb to older adults with early-stage AMD educe\nor avoid side effects.","PeriodicalId":31094,"journal":{"name":"Ciencia y Tecnologia para la Salud Visual y Ocular","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ginkgo Biloba Extract 761 Reduces the Risk of Progression of\\nAge-Related Macular Degeneration\",\"authors\":\"Sergio Ramírez-González, E. Casillas-Casillas, F. Jaramillo-Juárez, A. Rincón-Sánchez\",\"doi\":\"10.19052/sv.vol20.iss2.7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Age-related macular degeneration (AMD) is the leading cause of blindness. Although its\\ndevelopment is poorly understood., high concentrations of reactive oxygen species, maybe trigger\\nit. The aim of this study was to analyze whether the antioxidant action of the dietary supplement\\nGinkgo biloba (EGb-761) can reduce the progression of AMD. A clinical trial was conducted in\\nMexico, with people over 55 years of age. AMD patients were treated with EGb-761: 50 mg/day\\n(n = 26) or 100 mg/day (n = 22) for 3 months. A control group with 22 healthy people (without\\ntreatment) was included. Before and after treatment, functional and structural ocular tests were\\nperformed, and systemic oxidative stress (OS) was measured.Changes between baseline and after\\nthe treatment with both doses were significant (P < 0.05). Contrast sensitivity increased 16% and\\n17%, the number of metamorphopsias (central vision integrity) decreased 100% and 95%;\\ncentral perimetry (scotoma) decreased 93% and 88%, and hyperpigmentation\\n(autofluorescence) decreased 88% and 89%, respectively. For OS, malondialdehyde\\nconcentration decreased 7.6% and 8.5%, and reduced glutathione levels increased 5.3% and\\n7.1%, respectively. We suggest giving low doses of Gb to older adults with early-stage AMD educe\\nor avoid side effects.\",\"PeriodicalId\":31094,\"journal\":{\"name\":\"Ciencia y Tecnologia para la Salud Visual y Ocular\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ciencia y Tecnologia para la Salud Visual y Ocular\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.19052/sv.vol20.iss2.7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ciencia y Tecnologia para la Salud Visual y Ocular","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19052/sv.vol20.iss2.7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ginkgo Biloba Extract 761 Reduces the Risk of Progression of
Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of blindness. Although its
development is poorly understood., high concentrations of reactive oxygen species, maybe trigger
it. The aim of this study was to analyze whether the antioxidant action of the dietary supplement
Ginkgo biloba (EGb-761) can reduce the progression of AMD. A clinical trial was conducted in
Mexico, with people over 55 years of age. AMD patients were treated with EGb-761: 50 mg/day
(n = 26) or 100 mg/day (n = 22) for 3 months. A control group with 22 healthy people (without
treatment) was included. Before and after treatment, functional and structural ocular tests were
performed, and systemic oxidative stress (OS) was measured.Changes between baseline and after
the treatment with both doses were significant (P < 0.05). Contrast sensitivity increased 16% and
17%, the number of metamorphopsias (central vision integrity) decreased 100% and 95%;
central perimetry (scotoma) decreased 93% and 88%, and hyperpigmentation
(autofluorescence) decreased 88% and 89%, respectively. For OS, malondialdehyde
concentration decreased 7.6% and 8.5%, and reduced glutathione levels increased 5.3% and
7.1%, respectively. We suggest giving low doses of Gb to older adults with early-stage AMD educe
or avoid side effects.